CELC Stock Summary and Trading Ideas (Celcuity | NASDAQ:CELC)

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Celcuity trades on the NASDAQ stock market under the symbol CELC.

As of April 17, 2026, CELC stock price declined to $122.46 with 456,643 million shares trading.

CELC has a beta of 0.07, meaning it tends to be less sensitive to market movements. CELC has a correlation of 0.00 to the broad based SPY ETF.

CELC has a market cap of $5.92 billion. This is considered a Mid Cap stock.

In the last 3 years, CELC traded as high as $127.34 and as low as $7.58.

The top ETF exchange traded funds that CELC belongs to (by Net Assets): VTI, IWM, XBI, VXF, IWO.

CELC has outperformed the market in the last year with a price return of +1095.9% while the SPY ETF gained +36.3%. CELC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +14.5% and +8.7%, respectively, while the SPY returned +2.9% and +8.3%, respectively.

CELC support price is $120.73 and resistance is $129.77 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CELC shares will trade within this expected range on the day.